You haven't searched anything yet.
Ascendis Pharma is a dynamic, fast-growing global biopharmaceutical company with locations in Denmark, Europe, and the United States. Today, we're advancing programs in Endocrinology Rare Disease and Oncology.
Here at Ascendis, we pride ourselves on exceptional science, visionary leadership, and skilled and passionate colleagues.
Guided by our core values of Patients, Science, and Passion, we use our TransCon® drug development platform to fulfill our mission of developing new and potentially best-in-class therapies to address unmet medical needs.
Our culture fosters a place where skilled, adaptable, and highly resourceful professionals can truly make their mark. We offer a dynamic workplace for employees to grow and develop their skills.
Ascendis Pharma is looking to hire an experienced Associate Director, Market Access, Payor and Channel Marketing to join our team. Responsibilities will include developing and executing market access strategies and tactics across all relevant customer segments for products in our Endocrinology Rare Disease portfolio, with a primary focus on supporting the anticipated launch of an investigational treatment for hypoparathyroidism currently under review by the FDA. This role requires the ability to be both strategic and tactical, demonstrating strong leadership, project management, and communication skills. The level of the position will be determined and will be commensurate with the experience of the identified candidate.
This role is accountable implementation and refinement of the market access marketing plan through innovative thinking and collaboration with cross functional teams such as Pricing, Contracting & Distribution (PCD), Brand Marketing, Medical Affairs, Finance, Legal, other Market Access colleagues, external customers and agency partners.
This is a hybrid role that will be based in Princeton, NJ three (3) days/week and will report directly to the Senior Director, National Accounts & Payor Strategy.
Responsibilities
Full Time
$167k-212k (estimate)
07/12/2024
09/10/2024